Talk:Olodaterol

Update to article
WikiProject Pharmacology group and all other editors,

After writing to the WikiProject Pharmacology community with the suggestions for an update to this article, I wanted to now make those edits - the text beforehand had a few inaccuracies and wanted to update the article with more recent additions to keep the information up-to-date. As stated, I did post the suggested text to the WikiProject Pharmacology group on 18th Feb to ask for a consensus in favor, http://en.wikipedia.org/wiki/Wikipedia_talk:WikiProject_Pharmacology#Update_to_current_Olodaterol_Article and was told that the edit is neutral in tone and could be added.

If there is any community feedback, please let me know here or via my Talk page. Looking forward,--Christoph Hallmann (talk) 12:27, 7 May 2013 (UTC)


 * Thanks for expanding the article! I just formatted the references and added the planned trade name. Two of the external links you provided don't work for me (I've marked them with [dead link]). Do they need subscription? However, I don't see this as a real problem, as you provided plenty of accessible sources. In fact, there aren't many articles of this size with so many references!
 * Cheers, ἀνυπόδητος (talk) 19:02, 8 May 2013 (UTC)

I would like to propose a number of updates for the current article for olodaterol. Information on recently reported scientific data (for example, in the June 2014 issue of the International Journal Of COPD and CHEST 2014), relevant to the approved indication of olodaterol as a treatment for chronic pulmonary obstructive disease is missing in the introductory, ‘Medical Uses’ and ‘History’ sections of the current article. We also suggest adding a ‘Clinical Trials’ section to report the recent Phase III data. Below I have highlighted some suggested edits for inclusion in the article, for your consideration. Please note, the edits are highlighted in yellow with the previously approved language also copied across for ease of review. I look forward to hearing your thoughts on this suggestion and, as always, am grateful for any feedback and advice.

To be added to medical uses: ..... Respimat Soft Mist inhaler. Olodaterol was specifically designed to complement tiotropium (marketed as Spiriva®). Like tiotropium, olodaterol has a once-daily proven 24-hour profile. Also, olodaterol has matching pharmacodynamics to tiotropium. A fixed-dose combination of tiotropium and olodaterol (tiotropium + olodaterol Respimat® FDC) has been submitted for Marketing Authorisation in Europe and the US as a once-daily maintenance treatment for patients with COPD. Clinical trial section:

Clinical trials

An extensive clinical study programme has shown that, added to usual care, olodaterol significantly improves lung function (FEV1) in COPD patients, with a long-lasting and fast acting effect. A replicate pair of 48-week Phase III studies published in June 2014 in the International Journal of COPD examined the efficacy and safety of olodaterol in COPD patients.2 These studies, conducted in the USA, Germany, Australia, New Zealand, China, and Taiwan, compared olodaterol Respimat® to placebo on top of usual care in a total of 1,266 treated patients with moderate to very severe COPD. Olodaterol produced statistically significant improvements in lung function (both trough FEV1 and FEV1 AUC0-3) and decreased use of rescue medication compared to placebo, with safety and tolerability similar to those of placebo.2 More data from these studies, published in July 2014, also in the International Journal of COPD, showed that more COPD patients treated with olodaterol achieved clinically meaningful improvements in their quality of life compared to the group receiving placebo. The two 12-week ANHELTO 1 and 2 studies evaluated the efficacy and safety of combining olodaterol Respimat® with tiotropium HandiHaler® compared to tiotropium HandiHaler® monotherapy in patients with moderate to severe COPD. The studies showed that, after 12 weeks, the combination of olodaterol and tiotropium provided significantly greater improvements in lung function (FEV1 AUC0-3 and trough FEV1 response) and quality of life (as measured by St Georges Respiratory Questionnaire total scores) than tiotropium and placebo.

History: ....-was announced by the manufacturer. [10] By the end of 2014, olodaterol Respimat® had received national approval as a COPD maintenance therapy in over 40 countries.

References: 1. Data on file, pooled analysis from studies 122.39 and .40 2. Ferguson GT, Feldman GJ, Hofbauer P, et al. Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014; 9: 629—645 3. Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014; 9: 697–714. 4.ZuWallack R, Allen L, Hernandez, et al. Efficacy and safety of combining olodaterol Respimat® and tiotropium HandiHaler® in patients with COPD: results of two randomized, double-blind, active-controlled studies. Int J Chron Obstruct Pulmon Dis. 2014; 9: 1133–1144. Christoph Hallmann (talk) 08:17, 2 April 2015 (UTC)